Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Eligard is a prescription gonadotropin-releasing hormone agonist containing leuprolide acetate in an extended-release subcutaneous formulation. It is indicated for advanced prostate cancer. Four strengths release medicine over one, three, four, or six months and are administered by a healthcare professional.
read more about eligard ...Leuprolide initially stimulates pituitary gonadotropin release. Continued treatment then suppresses luteinizing hormone and follicle-stimulating hormone secretion, which reduces testicular testosterone production. This sustained androgen suppression is the basis for Eligard treatment in advanced prostate cancer.
Eligard is indicated for treatment of advanced prostate cancer. Safety and efficacy have not been established in pediatric patients. Treatment usually continues after development of castration-resistant prostate cancer, commonly alongside additional prostate cancer therapy when clinically indicated.
Eligard is injected subcutaneously as 7.5 mg every month, 22.5 mg every three months, 30 mg every four months, or 45 mg every six months. The formulation is mixed immediately before administration, and the injection site is varied periodically.
Eligard can cause an early testosterone surge that worsens bone pain, urinary obstruction, neuropathy, or spinal cord compression. Other serious concerns include hyperglycemia, diabetes, myocardial infarction, sudden cardiac death, stroke, QT prolongation, convulsions, and severe skin reactions. Blood glucose and cardiovascular risk require ongoing clinical attention.
Eligard is approved for treatment of advanced prostate cancer.
Depending on the strength, Eligard is given every month, every three months, every four months, or every six months.
Yes. Continued leuprolide treatment suppresses gonadotropin secretion and reduces testicular testosterone production.
Yes. An early testosterone surge can temporarily worsen prostate cancer symptoms during the first weeks of treatment.
Drugs Approved for Prostate Cancer. https://www.cancer.gov/about-cancer/treatment/drugs/prostate. Date Accessed September 29, 2026.
ELIGARD (Leuprolide Acetate) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7b679a9-6823-4ef8-8d31-3ab5058ffcfc. Date Accessed September 29, 2026.
Hormone Therapy for Prostate Cancer. https://www.cancer.gov/types/prostate/prostate-hormone-therapy-fact-sheet. Date Accessed September 29, 2026.
Leuprolide Acetate. https://www.cancer.gov/about-cancer/treatment/drugs/leuprolideacetate. Date Accessed September 29, 2026.
Leuprolide Injection: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a685040.html. Date Accessed September 29, 2026.